Investigation of laboratory and clinical parameters in the background of thrombosis in celiac disease and inflammatory bowel diseases
- Conditions
- Celiac disease, inflammatory bowel disease (Crohn’s disease and ulcerative colitis)Digestive SystemCoeliac disease, inflammatory bowel disease
- Registration Number
- ISRCTN49677481
- Lead Sponsor
- Centre for Translational Medicine
- Brief Summary
2019 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/30904871 protocol (added 09/04/2020) 2020 Results article in https://pubmed.ncbi.nlm.nih.gov/33259164/ (added 23/11/2021) 2019 Abstract results in https://onlinelibrary.wiley.com/doi/10.1177/2050640619854671 Abstract P2052; UEG - United European Gastroenterology Week 2019 Poster Presentations (added 11/07/2023)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 212
CD patients
1. Newly diagnosed or followed-up patients (with or without adhering to a gluten-free diet (GFD)
2. Aged =18 years
3. Diagnosis should meet the current guidelines (ESPHGAN, American College of Gastroenterology)
IBD patients
1. Newly diagnosed and followed-up patients
2. Aged =18 years
3. Diagnosis should meet the current guidelines (ECCO)
Non-CD, non-IBD controls
1. Aged =18 years
2. Celiac disease excluded (lack of symptoms and negative celiac-specific serology)
3. IBD excluded (lack of clinical, biochemical, endoscopic or radiologic signs of the disease)
1. Estimated glomerular filtration rate calculated with CKD-EPI formula <60 ml/min/1.73 m2 (CKD Stage 3 or more severe kidney failure)
2. Liver cirrhosis (Child-Pugh class B/C)
3. Heart failure (NYHA class III/IV)
4. Malignant diseases (except for cured cases)
5. Acute diseases within 2 weeks of sampling
6. Patients unable to understand the essentials of the informed consent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method